NCT04526834View on ClinicalTrials.gov

Phase 1 Study of Autologous CD30.CAR-T in Relapsed or Refractory CD30 Positive Non-Hodgkin Lymphoma

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

September 8, 2021

Primary Completion Date

November 22, 2022

Study Completion Date

March 31, 2036

Conditions
Anaplastic Large Cell LymphomaPeripheral T Cell LymphomaExtranodal NK/T-cell LymphomaDiffuse Large B Cell LymphomaPrimary Mediastinal Large B-Cell Lymphoma (PMBCL)
Interventions
DRUG

CD30.CAR-T

"Bendamustine and Fludarabine (3 days)~Dose level 1: 2 x 108 cell/m2 CD30.CAR-T (Day 0)~Dose level 2: 4 x 108 cell/m2 CD30.CAR-T (Day 0)~Dose level 3: 6 x 108 cell/m2 CD30.CAR-T (Day 0)"

Trial Locations (4)

37203

Sarah Cannon Research Institute, Nashville

77030

Baylor College of Medicine, Houston

The University of Texas MD Anderson Cancer Centre, Houston

91010

City of Hope, Duarte

Sponsors

Lead Sponsor

Tessa Therapeutics
All Listed Sponsors
lead

Tessa Therapeutics

INDUSTRY

NCT04526834 - Phase 1 Study of Autologous CD30.CAR-T in Relapsed or Refractory CD30 Positive Non-Hodgkin Lymphoma | Biotech Hunter | Biotech Hunter